KURA ONCOLOGY, INC. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6e746f14-59e3-4f55-826a-a7c88d27b998/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-303.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-092567 |
| FY 2024 | $-193.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029975 |
| FY 2023 | $-165.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-25-029975 |
| FY 2022 | $-139.9M | 2022-01-01 – 2022-12-31 | evidence 0000950170-25-029975 |
| FY 2014 | $-23.9k | 2014-01-01 – 2014-12-31 | evidence 0001213900-15-001429 |
| FY 2013 | $-160.9k | 2007-11-16 – 2014-03-31 | evidence 0001213900-14-003353 |
| FY 2012 | $-138.8k | 2007-11-16 – 2013-03-31 | evidence 0001144204-13-029422 |
| FY 2011 | $-115.9k | 2007-11-16 – 2012-03-31 | evidence 0001144204-12-029113 |
| FY 2010 | $-20.5k | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-018805 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).